Spain Antibody Drug Conjugates Market Size & Outlook
Spain antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Spain antibody drug conjugates market highlights
- The Spain antibody drug conjugates market generated a revenue of USD 120.0 million in 2021 and is expected to reach USD 573.7 million by 2030.
- The Spain market is expected to grow at a CAGR of 19% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 120.0 million |
| Market revenue in 2030 | USD 573.7 million |
| Growth rate | 19% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Spain accounted for 2.1% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 72.17% in 2021. Horizon Databook has segmented the Spain antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Spain has a growing incidence of cancer, primarily driven by an aging population and high tobacco & alcohol consumption, particularly in men. As per the International Agency for Research on Cancer, there were 282,000 new cases of cancer in 2020, led by prostate cancer and breast cancer in men & women, respectively.
Moreover, the incidence of cancer is expected to increase further by ~17% to reach 330,000 cases by 2030. Hence, the Spanish Ministry of Health, along with the ten other countries, signed the Valletta Declaration to jointly negotiate the price of expensive pharmaceuticals, including advanced cancer therapeutics, to improve patient access to new & innovative medicines.
The increasing incidence of cancer is expected to drive the adoption of ADCs. Spanish companies such as Pharma Mar are involved in the advanced research of ADC drugs. Pharma Mar is currently developing marine-based cancer drugs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain antibody drug conjugates market size, by application, 2018-2030 (US$M)
Spain Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
